246 Results

People

  1. Bajorin
    Bajorin
  2. Oettgen
    Oettgen
  3. Wong
    Wong
  4. Cheung
    Cheung
  5. Giralt
    Giralt
  6. Kelsen
    Kelsen
  7. Kemeny
    Kemeny
  8. Horwitz
    Horwitz
  9. O'Reilly
    O'Reilly
  10. Perales
    Perales

Groups

  1. Department of Medicine (137)
  2. Solid Tumor Oncology Division (69)
  3. Hematologic Malignancies, Division of (66)
  4. Center for Hematologic Malignancies (60)
  5. Surgery (29)
  6. Survivorship Research (29)
  7. GSK Faculty (26)
  8. Pediatrics, Department of (22)
  9. Adult Leukemia (20)
  10. Division of Subspecialty Medicine (19)
  1. "hypotension"
Formats
  1. Journal Article (226)
  2. Review (10)
  3. Conference Paper (3)
  4. Guidelines (2)
  5. Research Letter (2)
  6. Book Section (1)
  7. Correspondence (1)
  8. Editorial (1)
Groups
  1. Department of Medicine (137)
  2. Solid Tumor Oncology Division (69)
  3. Hematologic Malignancies, Division of (66)
  4. Center for Hematologic Malignancies (60)
  5. Surgery (29)
  6. Survivorship Research (29)

More Groups

People
  1. Dean Bajorin (11)
  2. Nancy Kemeny (9)
  3. George Wong (7)
  4. Herbert Oettgen (7)
  5. Paul Chapman (7)
  6. David Kelsen (6)

More People

Years
  1. 2025 (11)
  2. 2024 (12)
  3. 2023 (8)
  4. 2022 (8)
  5. 2021 (4)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Cancer (13)
  3. Blood (12)
  4. Lancet Oncology (12)
  5. Clinical Cancer Research (9)
  6. Gynecologic Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (37)
  2. Elsevier Science, Inc. (19)
  3. Springer (18)
  4. Wiley Blackwell (18)
  5. American Society of Clinical Oncology (16)
  6. American Society of Hematology (14)

More Publishers

Results (246)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Role of artificial intelligence in critical care nutrition support and research
    Review

    Kittrell, H. D.; Shaikh, A.; Adintori, P. A.; McCarthy, P.; Kohli-Seth, R.; Nadkarni, G. N.; Sakhuja, A.
    Nutrition in Clinical Practice (2024)

    Fulltext@MSK | Save
  • The Princeton IV consensus recommendations for the management of erectile dysfunction and cardiovascular disease
    Guidelines

    Köhler, T. S.; Kloner, R. A.; Rosen, R. C.; Burnett, A. L.; Blaha, M. J.; Ganz, P.; Goldstein, I.; Kim, N. N.; Lue, T.; McVary, K. T.; more...
    Mayo Clinic Proceedings (2024)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T-cells: A review on current status and future directions for relapsed/refractory multiple myeloma
    Review

    Hamadeh, I. S.; Friend, R.; Mailankody, S.; Atrash, S.
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Vital sign data quality: Not just a retrospective research problem
    Editorial

    McCormick, P. J.
    Anesthesiology (2024)

    Fulltext@MSK | Save
  • Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Focus on the use of tagraxofusp and clinical considerations
    Review

    Pemmaraju, N.; Madanat, Y. F.; Rizzieri, D.; Fazal, S.; Rampal, R.; Mannis, G.; Wang, E. S.; Foran, J.; Lane, A. A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • A whole-food, plant-based randomized controlled trial in metastatic breast cancer: Weight, cardiometabolic, and hormonal outcomes
    Journal Article

    Campbell, T. M.; Campbell, E. K.; Culakova, E.; Blanchard, L. M.; Wixom, N.; Guido, J. J.; Fetten, J.; Huston, A.; Shayne, M.; Janelsins, M. C.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
    Journal Article

    Yankelevich, M.; Thakur, A.; Modak, S.; Chu, R.; Taub, J.; Martin, A.; Schalk, D.; Schienshang, A.; Whitaker, S.; Rea, K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: Active drug monitoring to assess the impact of immune response on drug exposure
    Journal Article

    Spreafico, A.; Couselo, E. M.; Irmisch, A.; Bessa, J.; Au-Yeung, G.; Bechter, O.; Svane, I. M.; Sanmamed, M. F.; Gambardella, V.; McKean, M.; more...
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save